Alternatives to IMU Biosciences

Leveraging AI and a massive patient tissue dataset to accelerate drug discovery and advance precision medicine.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.

Scalable, one-time curative in-vivo gene editing therapies.

Developing precision medicines for inflammatory and immune-mediated diseases using AI and patient sample analysis.

Engineering-driven DNA design platform to overcome biological barriers in genetic medicines.

Advancing biopsy specimen stewardship and expanding access to precision oncology.

Biotechnology company defining membrane protein spatial relationships to create novel therapeutics for cancer and autoimmune diseases.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Developing an automated platform for liquid biopsy sample preparation.

Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.

Biotechnology company leveraging ultracompact CRISPR systems for gene editing therapies and diagnostics.

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

A life sciences company that has developed a high-throughput platform for mapping molecular cell architecture at nanoscale resolution.

Spatial multiomics company developing technologies for single-cell gene expression profiling in intact tissues.

A vertically-integrated procurement platform for the life sciences industry.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.